234 followers
Paper 2 from my PhD! It’s obviously very interesting and you should download immediately 😁
Paper 2 from my PhD! It’s obviously very interesting and you should download immediately 😁
RT @HughesDyfrig: New research with @hcattPH How to assess the benefit-risk of #biosimilars in extrapolated indications? Where, benefits =…
Value assessment of Infliximab #biosimilar in Crohn's https://t.co/VkW67pFY82 @HughesDyfrig et al.. #biosimilars
New research with @hcattPH How to assess the benefit-risk of #biosimilars in extrapolated indications? Where, benefits = reduced cost risk = uncertain effects https://t.co/9vJxcu8LeZ @MRCHTMRNetwork
#HealthEconJA Value Assessment and Quantitative Benefit-Risk Modelling of Biosimilar Infliximab for Crohn’s Disease https://t.co/1pSpKzccpK